Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) hit a new 52-week high on Friday . The stock traded as high as $80.98 and last traded at $79.3130, with a volume of 88102 shares trading hands. The stock had previously closed at $77.00.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a report on Wednesday, November 5th. Barclays assumed coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Evercore raised their price objective on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Finally, Mizuho set a $81.00 price objective on Henry Schein and gave the company a “neutral” rating in a research report on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein currently has an average rating of “Hold” and an average target price of $76.42.
Read Our Latest Analysis on Henry Schein
Henry Schein Trading Up 3.5%
Hedge Funds Weigh In On Henry Schein
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein during the second quarter worth $25,000. MUFG Securities EMEA plc purchased a new stake in Henry Schein during the 2nd quarter worth $27,000. Flagship Harbor Advisors LLC purchased a new stake in Henry Schein during the 4th quarter worth $30,000. ANTIPODES PARTNERS Ltd acquired a new position in Henry Schein in the 2nd quarter worth $43,000. Finally, Steph & Co. purchased a new position in Henry Schein in the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
See Also
- Five stocks we like better than Henry Schein
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The $650 Million Bet on AI’s Future
- The gold chart Wall Street is terrified of…
- Trump’s AI Secret: 100X Faster Than Nvidia
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
